FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF DERMATITIS AND INFLAMMATORY SKIN DISEASES

1 . A pharmaceutical composition comprising a cannabinoid and a siloxane wherein the cannabinoid is dissolved in the composition.

2 . The pharmaceutical composition according to claim 1 wherein the cannabinoid is cannabidiol.

3 . The pharmaceutical composition according to claim 1 wherein the composition is for topical application.

4 . The pharmaceutical composition according to claim 1 wherein the siloxane is selected from the group consisting of: hexamethyldisiloxane, octamethyltrisiloxane and combinations thereof.

5 . The pharmaceutical composition according to claim 1 further comprising a residual solvent.

6 . The pharmaceutical composition according to claim 5 wherein the residual solvent is selected from the group consisting of: alkyl polypropylene glycol/polyethylene glycol ether (alkyl PEG/PPG ether) and a fatty alcohol.

7 . The pharmaceutical composition according to claim 6 wherein the alkyl PEG/PPG ether:

a) has a PEG/PPG chain length of between 10-50 PG units and an ether component of between 2-20 carbons, wherein the sum of the PG units and the carbons of the ether component is between 20 and 60;

b) has a low volatility such that less than 5% would evaporate at skin temperature over 24 hours;

c) is a liquid at about 30° C., or less; and/or

d) is selected from the group consisting of: polypropylene glycol ethers of stearyl alcohol and butyl alcohol.

8 . The pharmaceutical composition according to claim 6 wherein the relative amount of alkyl PEG/PPG ether is selected from the following group: at least 1% w/w, at least 2% w/w, at least 3% w/w, at least 4% w/w, and at least 5% w/w.

9 . The pharmaceutical composition according to claim 6 wherein the fatty alcohol:

a) has a low volatility such that less than 5% would evaporate at skin temperature over 24 hours;

b) is a C 12-22 fatty alcohol and/or

c) is a liquid at about 30° C., or less.

10 . The pharmaceutical composition according to claim 9 wherein the fatty alcohol is selected from the group consisting of: oleyl alcohol, isostearyl alcohol, octyldodecyl alcohol, and 2-hexyl decyl alcohol.

11 . The pharmaceutical composition according to claim 1 further comprising a low molecular weight alcohol.

12 . The pharmaceutical composition according to claim 11 wherein the low molecular weight alcohol is selected from the group consisting of C 2-6 alcohols, and combinations thereof.

13 . The pharmaceutical composition according to claim 12 wherein the alcohol is selected from the group consisting of: ethyl alcohol, n-propanol, isopropyl alcohol and combinations thereof.

14 . The pharmaceutical composition according to claim 1 characterised in that the concentration of cannabinoid in the topical composition is at least 2% w/w.

15 . The pharmaceutical composition according to claim 1 characterised in that the concentration of cannabinoid in the topical composition is at least 20% w/w.

16 . A method for treating or preventing an inflammatory skin condition in a patient in need of such treatment, the method comprising topically administering a prophylactically or therapeutically effective amount of a pharmaceutical composition according to claim 1 .

17 . (canceled)

18 . (canceled)